Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Soleno Therapeutics (SLNO) Debt to Equity (2025)

Soleno Therapeutics (SLNO) has disclosed Debt to Equity for 4 consecutive years, with $0.11 as the latest value for Q4 2025.

  • Quarterly Debt to Equity changed N/A to $0.11 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.11 through Dec 2025, changed N/A year-over-year, with the annual reading at $0.11 for FY2025, N/A changed from the prior year.
  • Debt to Equity for Q4 2025 was $0.11 at Soleno Therapeutics, up from $0.1 in the prior quarter.
  • The five-year high for Debt to Equity was $0.21 in Q1 2025, with the low at $0.1 in Q3 2025.